The QualityStocks Daily Monday, January 3rd, 2022

Today's Top 3 Investment Newsletters

BioMedWire(GNPX) $3.5000 +167.18%

PennyPickGains(SUIC) $0.8097 +118.84%

Buzz Stocks(IMMX) $5.7800 +62.36%

The QualityStocks Daily Stock List

Artificial Intelligence Technology Solutions (AITX)

QualityStocks, The Street Report, Investors Alley and InvestorPlace reported earlier on Artificial Intelligence Technology Solutions (AITX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Artificial Intelligence Technology Solutions Inc. (OTC: AITX) is focused on delivering robotic and artificial intelligence solutions for monitoring, security and operational needs. The company’s AI technologies are supported by custom cloud and software services and paired with multi-use hardware, which helps to intelligently integrate and automate operational, concierge and security tasks.

The firm has its headquarters in Reno, Nevada and was founded by John B. Crawford in 2010, on March 25. Before changing its name in August 2018 to Artificial Intelligence Technology Solutions Inc., the firm was known as On The Move Systems Corp. The company serves consumers in the U.S. and in particular, automobile fleet administrators and vehicle dealerships.

The company operates through its wholly-owned subsidiaries, one of which is Robotic Assistance Devices Inc. The subsidiary develops unique technology, specifically; mobileware, cloudware, software and hardware, which are used in the development of powerful tools like RADGuard, RADPMC and RADSOC as well as to improve performance in companies.

The firm is also engaged in the provision of mobile electronic services and offers after-market video, audio and electronic upgrades for boats, recreational vehicles and automobiles.

The company recently entered into an agreement with EAGL Technology Inc. for the provision of the latter firm’s gunshot detection system in all present and future RAD devices. The integration of EAGL solutions into the innovative products will not only make the products more popular but also expand their reach into the markets they serve, which will be good for investments as well as the firm’s stock.

Artificial Intelligence Technology Solutions (AITX), closed Monday's trading session at $0.0219, up 44.9851%, on 68,303,319 volume with 1,793 trades. The average volume for the last 3 months is 68.303M and the stock's 52-week low/high is $0.0145/$0.2899.

Creative Medical Technology Holdings (CELZ)

QualityStocks and Schaeffer's reported earlier on Creative Medical Technology Holdings (CELZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (OTC: CELZ) is a clinical-stage biotechnology firm that is engaged in the treatment of various neurological, orthopedic, urological and immunological ailments such as stroke and erectile dysfunction, using adult stem cell treatments.

The firm is based in Phoenix, Arizona and was incorporated in 1998, on December 3. The enterprise, together with Creative Medical Health Inc. its affiliate company, is focused on regenerative medical solutions for unmet neurological and urological needs. Their team is made up of international researchers focused on regenerative medicine, whose approach to treatments makes sure that all treatments are proven to be both effective and safe.

Through partnerships with leading academic institutions and researchers, the firm has developed treatments for erectile dysfunction, established an extensive intellectual property portfolio, developed proprietary protocols and obtained Amniostem; a groundbreaking stem cell. The company is currently breaking new ground for the treatment of stroke using its amniotic-fluid based stem cell and recently launched a patient trial for erectile dysfunction at UCLA.

The firm’s product portfolio includes a treatment indicated for female infertility called OvaStem; a candidate developed for stroke patients, dubbed ImmCelz; Amniostem for the treatment of glioma, toxicity and strokes; a treatment developed for chronic lower back pain christened StemSpine; a candidate indicated for the treatment of genital dryness and loss of genital sensitivity and a treatment developed for erectile dysfunction called CaverStem.

Creative Medical Technology Holdings Inc. recently announced that the FDA issued an Investigational New Drug number to the firm’s ImmCelz candidate, which was developed to treat stroke patients. This is a major milestone for the firm and may lead to the candidate being approved for commercialization and use in the near future, which will be beneficial not only to the patients whose needs will be met but also to the company.

Creative Medical Technology Holdings (CELZ), closed Monday's trading session at $3.2, up 44.7964%, on 64,281,199 volume with 231,080 trades. The average volume for the last 3 months is 64.002M and the stock's 52-week low/high is $0.0121/$9.00.

Galaxy Next Generation (GAXY)

QualityStocks, StockRockandRoll, StockOnion, Profitable Trader Authority, Penny Pick Finders, OTCtipReporter, PennyStockLocks, Buzz Stocks, PennyStockProphet, SmallCapVoice, HotOTC, Penny Stock 101, PennyStockScholar, Small Cap Firm, Planet Penny Stocks, Innovative Marketing, Insider Financial, MicroCapDaily, OTCMagic, AwesomeStocks, Penny Stock 113, WallStreetPR and Penny Stock 107 reported earlier on Galaxy Next Generation (GAXY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Galaxy Next Generation Inc. (OTCQB: GAXY) is a holding company that is focused on the distribution of audio solutions and interactive learning technologies. Its software and hardware enables participants and presenters to fully engage in an instructional environment.

The firm is based in Toccoa, Georgia and was incorporated in 1991 by Steven Whitten. It has its own resell channel that sells directly to the Southeastern part of the U.S. The firm’s distribution channel is made up of nearly thirty resellers across the U.S. who mainly sell its product in the educational and commercial market. It offers its services to its consumers, which include maintenance, training and installation services.

The enterprise’s products, which create an interactive and immersive experience, are helping to evolve teaching and learning through their Connected Classrooms. In addition, they are empowering teachers with a new way to engage with and motivate their students in learning activities.

The firm’s products include various international and national branded communication and peripheral devices as well as its own private-label interactive touch screen. It also develops school public address and classroom audio solutions as well as Intercom products and accessories.

The enterprise recently announced that it had received a purchase order from an OEM customer for its innovative audio products and accessories. The firm’s CEO noted that they were working on reducing lead times and acquiring components in bigger quantities, in a bid to increase the build time and meet their consumer’s timing and needs. The firm is investing in their OEM division as part of their extensive expansion plan.

Galaxy Next Generation (GAXY), closed Monday's trading session at $0.00785, up 33.0508%, on 25,758,710 volume with 273 trades. The average volume for the last 3 months is 25.759M and the stock's 52-week low/high is $0.004/$0.282.

Sino United Worldwide Consolidated Ltd. (SUIC)

MarketBeat, QualityStocks, Pennystockmania, PennyPickGains, StocksEarning and Innovative Marketing reported earlier on Sino United Worldwide Consolidated Ltd. (SUIC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sino United Worldwide Consolidated Ltd. is a FinTech (Financial Technology) company. It provides Venture Financing and Blockchain services to five sectors. These include “Logistics & Trade”, “Vehicle & Transportation”, “Finance & Coin”, and “Medical & Healthcare”, and a new addition, “FinTech.” The Company previously went by the name AJ Greentech Holdings Ltd. It changed its name to Sino United Worldwide Consolidated Ltd. in July of 2017. Established in 2009, the Company is based in Flushing, New York. Sino United’s Asian operating center is located in Hong Kong and Singapore.

The Company’s primary business is in Blockchain, in 4 Sectors. These are Blockchain in Logistics and Trade; Blockchain in Vehicle and Transportation; Blockchain in Finance And Coin; and Blockchain in Medical and Healthcare. The addition of the FinTech sector to Sino United’s Blockchain services includes a complete update in which the Company will build up its own internal capabilities through actively starting a Blockchain training program, developing a 3rd generation Smart Contract Blockchain under the Sino United brand, and using these capabilities to provide a comprehensive ICO consultancy.

Sino United Worldwide Consolidated and USADAE (American Digital Asset Exchange) revealed the Joint Venture (JV) to launch the new FinTech trading platform, embarking on the first worldwide Blockchain conglomerate as a hub for innovative Blockchain technology and unique Blockchain projects. The partnership adjoins the sanctioned practices of regulated and inventive finance and exchanges and the present flourishing digital world enabled by Blockchain, Distributed Ledger and Artificial Intelligence (AI) technologies.

This Sino United-USADAE alliance offers clients security and storage services, and also trade execution for crypto, digital assets. The alliance will merge their strong trading platform technology and premium selection of digital tokens, adopting rigorous assessment utilizing the latest in proof-of-reputation algorithms and other advanced programs.

Sino United Worldwide Consolidated Ltd. (SUIC), closed Monday's trading session at $0.8097, up 118.8378%, on 90,477 volume with 103 trades. The average volume for the last 3 months is 90,477 and the stock's 52-week low/high is $0.30/$20.00.

Ascent Solar Technologies, Inc. (ASTI)

Profitable Trader Authority, Small Cap Firm, QualityStocks, OTCPicks, Investor Ideas, PennyStocks24, Alternative Energy, Top Stock Picks, SmarTrend Newsletters, StockEgg, StreetInsider, PennyTrader Publisher, The Street, BestOtc, AllPennyStocks, PennyToBuck, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, StockHotTips, PennyOmega, FeedBlitz, Promotion Stock Secrets, PennyStockVille, PennyPro, Penny Invest, MadPennyStocks, TopPennyStockMovers, Greenbackers, CoolPennyStocks, BUYINS.NET, BullRally, HotOTC, StockRich, PennyInvest, StockOodles, Stock Rocket Report, Stocks That Move, Street Insider, SmallCapVoice, The Online Investor, SuperStockHunter, SuperStockTips, Beacon Equity Research, Winston Small Cap, DSR News, Stockgoodies, The Stock Detective, Stock Specialists, WealthMakers, InvestorPlace, InvestorSoup, InvestorsUnderground, StockMister, Penny Stocks Finder, ProTrader, Shah's Insights & Indictments, Wise Alerts, TopStockAnalysts, TheStockWizards.net, Stock Market Authority, TradingMarkets, The Momentum Traders Network, Lebed.biz, PHUB News, MarketBeat, Penny Stock Pinnacle, Penny Stock Craze, Stock Preacher, PCG Advisory, Wall Street Resources, Momentum Traders, Mega Stock Picks, Rick Saddler and Stock News Now reported earlier on Ascent Solar Technologies, Inc. (ASTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ascent Solar Technologies, Inc. is a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions. It designs, manufactures, and sells PV integrated consumer electronics and portable power applications for commercial and military users. The Company markets and sells its products via distributors, value added resellers, as well as e-commerce companies.

Established in 2005, Ascent Solar Technologies is based in Thornton, Colorado, where its Research and Development (R&D) and its 30 MW nameplate production facility are. Ascent Solar modules were named as one of the top 100 technologies in both 2010 and 2015 by R&D Magazine. In addition, they were named one of TIME Magazine's 50 best inventions for 2011.

The Company is a developer of thin-film PV modules using flexible substrate materials that are more versatile and sturdy than traditional solar panels. The technology represents the leading edge of flexible power. It can be directly integrated into consumer products and off-grid applications, and also other aerospace applications. Ascent Solar Technologies provides solar solutions from bare modules to finished goods and everything in between.

The Company has its patented 3-step manufacturing process. Step 1 is thin-film deposition. Step 2 is monolithic integration. Step 3 is final assembly. Ascent’s inventive monolithic integration process enables the highest level of efficiency, durability and weight savings. This represents the potential to transform the way solar power can be used in everyday life. The Company’s solar technology and power solutions are for remote locations and extreme environments. Regarding its IP (Intellectual Property), Ascent Solar Technologies has more than 80 U.S. and International issued patents and published patent applications.

Ascent develops and manufactures its innovative CIGS (Copper-Indium-Gallium-Selenide) photovoltaic technology on a flexible, plastic substrate. The design of these panels are to convert sunlight into electric power through laying a thin layer of these four elements onto a plastic backing.

The Company is a leader in the CIGS field. It is the only manufacturer commercially producing CIGS solar on a plastic substrate with monolithic integration, which is an important differentiator for the Company.

Ascent Solar Technologies, Inc. (ASTI), closed Monday's trading session at $0.0039, up 56%, on 79,461,286 volume with 591 trades. The average volume for the last 3 months is 79.461M and the stock's 52-week low/high is $0.002/$0.097.

North American Cannabis Holdings, Inc. (USMJ)

QualityStocks, Wall Street Corner, Promotion Stock Secrets, Pennybuster, StockHideout, SmallCapVoice, PennyStockRumors.net, PennyPickAlerts and Fortune Stock Alerts reported earlier on North American Cannabis Holdings, Inc. (USMJ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

North American Cannabis Holdings, Inc., via its subsidiaries, operates in the legal cannabis market in the US. It conducts various pilots in the legal cannabis sector so as to explore different high growth potential business opportunities. The Company previously went by the name Algae International Group, Inc. It changed its name to North American Cannabis Holdings, Inc. in June of 2015. North American Cannabis Holdings is headquartered in Farmers Branch, Texas and lists on the OTC Markets.

Additionally, North American Cannabis operates a destination beverage company. It enables consumers to interface with staff to learn about the specific benefits of cannabis, and select healthy and refreshing cannabis infused beverages. These beverages include custom blended hemp infused coffee, cold pressed juices, and smoothies. Furthermore, the Company offers raw hemp seeds and other hemp infused foods.

North American Cannabis’ eCommerce site is www.USMJ.com. USMJ is a subsidiary company of North American Cannabis Holdings. USMJ partners with premier CBD producers. USMJ curates each product selection to work as promised and to ensure each item it sells is safe and effective.

North American Cannabis has a curated product line of legal cannabinoids and accessories. All of the Company’s products are lab-tested and contain no THC (tetrahydrocannabinol) through a carefully monitored extraction process.

North American Cannabis’ products are all natural, all safe, and all CBD (cannabidiol). The Company carries manifold CBD and CBG Smokable products in Pre Roll and Flower. It has greater than 150 CBD, Hemp, as well as Cannabis Essentials products available online.

Recently, North American Cannabis Holdings said that because of overwhelming demand, USMJ.com has streamlined its process to becoming a Vendor on USMJ.com. The USMJ.com Vendor program launched earlier but has been a slowly growing process.

Now, CBD/CBG Manufacturers and Vendors can apply and list their products on USMJ.com. Before now, it's been a series of emails. However, now there's a set discovery process to understand the products the Company is putting online and established marketing efforts to help businesses grow.

North American Cannabis Holdings, Inc. (USMJ), closed Monday's trading session at $0.0007, up 40%, on 165,678,804 volume with 146 trades. The average volume for the last 3 months is 165.679M and the stock's 52-week low/high is $0.0002/$0.008.

Rockley Photonics (RKLY)

MarketBeat and InvestorPlace reported earlier on Rockley Photonics (RKLY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rockley Photonics Holdings Ltd (NYSE: RKLY) is a holding firm that is focused on the development and supply of silicon photonics.

The firm has its headquarters in Cheshire, the United Kingdom and was incorporated in 2013. It operates as part of the business support services industry. The firm has five companies in its corporate family and serves consumers around the globe, with a focus on the United Kingdom.

The company is focused on hyper-scale data center connectivity and consumer wearables, mobile and medical devices in the health and wellness sectors. The company’s technology platform offers nutrition management, disease detection and preventive healthcare delivery through continuous health and wellness monitoring.

The enterprise has developed a 3rd generation application-specific silicon photonics platform that has been designed for optical integration challenges. It also develops an array of sensing products comprised of integrated optimal modules with supporting software, electronics, application algorithms and AI platforms for high-volume applications in high-growth and dynamic market sectors.The enterprise also provides mobile platform for different solutions, including AI and cloud analytics, sensing algorithms, electronic and photonic integrated circuits, firmware/software and hardware design and system architecture that are utilized in machine vision and health monitoring for data communications.

The firm, which is focused on the health monitoring space, is working to realize its goal to introduce new solutions to the health and wellness market that satisfy significant consumer demand. This will not only bring in more revenue into the firm but also encourage more investments into the company, which will boost its growth.

Rockley Photonics (RKLY), closed Monday's trading session at $4.56, up 4.8276%, on 459,478 volume with 2,546 trades. The average volume for the last 3 months is 455,504 and the stock's 52-week low/high is $4.14/$16.56.

Headwater Exploration (CDDRF)

MarketBeat reported earlier on Headwater Exploration (CDDRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Headwater Exploration Inc. (OTC: CDDRF) (TSE: HWX) (FRA: C6V) is a junior resource firm that is focused on exploring for, developing and producing natural gas and petroleum in the Western Canadian Sedimentary Basin.

The firm has its headquarters in Calgary, Canada and was incorporated in March 1995 by Charles M. MacDonald, Paul J. Hopkins and Norman W. Miller. Prior to its name change in March 2020, the firm was known as Corridor Resources Inc. It operates as part of the support activities for the mining industry. The firm has three companies in its corporate family and serves consumers in Canada and the United States.

The company is focused on providing superior corporate level returns by focusing on sustainability, strengthening its balance sheet and maintaining asset quality. It has offices in Calgary and Halifax as well as a field office near Sussex.

The enterprise’s main operating areas are Marten Hills and McCully Field. It owns natural gas production reserves in the McCully field; and oil production, lands and reserves in the Marten Hills area. The McCully field is situated roughly 10km northeast of Sussex in the Penobsquis farming community, while Marten Hills is found about 250 km north of Alberta, in the Clearwater play. In addition to this, the enterprise operates and owns a natural gas processing plant which has a processing capacity of about 35 million ft2 per day.

The company is focused on evolving with rapid growth and executing its corporate strategy. It continues to assess acquisition expansion opportunities in the Clearwater fairway, which will be good for its growth.

Headwater Exploration (CDDRF), closed Monday's trading session at $4.1, up 0.244499%, on 10,549 volume with 11 trades. The average volume for the last 3 months is 10,549 and the stock's 52-week low/high is $1.84/$4.55.

Falcon Minerals (FLMN)

MarketBeat, StreetInsider, QualityStocks, Trades Of The Day, Daily Trade Alert, Top Pros' Top Picks and StockMarketWatch reported earlier on Falcon Minerals (FLMN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Falcon Minerals Corp. (NASDAQ: FLMN) (FRA: 2JT) is an oil and gas minerals company that is focused on acquiring, developing and owning royalty interests, over-riding royalty interests and mineral interests in natural gas and oil properties in North America.

The firm has its headquarters in New York and was incorporated in 2016, on June 13th by Daniel C. Herz. It operates as part of the metals and mining industry, under the natural resources sector. The firm has twelve companies in its corporate family and serves consumers in the United States.

The company is focused on acquiring high growth core-of-the-core oil and gas minerals. Its business model provides a distinct advantage built around a strong balance sheet and high-margin cash flow. These advantages include low operating costs which yield high-margin cash flow and no capital spending requirements, enabling financial flexibility and return of majority of cash flow to shareholders.

The enterprise owns interests which cover roughly 250,000 gross unit acres in Austin Chalk and Eagle Ford in Gonzales County, DeWitt County and Karnes County, Texas. It also owns royalty interests that cover about 80,000 gross unit acres in the Appalachian region, which comprises of Ohio, West Virginia and Pennsylvania.

The firm recently reported its latest financial results for 2021, with its CEO noting that its assets performed well in the third quarter. The firm’s free cash flow will offer an attractive yield to investors, which may help bring in more investors. Currently, it is focused on driving value for its shareholders, which will have a positive effect on investments into the firm.

Falcon Minerals (FLMN), closed Monday's trading session at $5.07, up 4.1068%, on 465,268 volume with 3,213 trades. The average volume for the last 3 months is 465,268 and the stock's 52-week low/high is $3.05/$6.58.

Alpha Cognition (ACOGF)

We reported earlier on Alpha Cognition (ACOGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alpha Cognition Inc. (OTCQB: ACOGF) (CVE: ACOG) is a clinical stage biopharmaceutical firm that is engaged in the development of treatments for amyotrophic lateral sclerosis and Alzheimer’s disease.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2000. Prior to its name change in March 2021, the firm was known as Crystal Bridge Enterprises Inc. It serves consumers around the globe.

The company is focused on neurological disease research and uses a portfolio approach to identify and develop bioactives for the treatment of neurological ailments as well as for neuroprotection. The company identifies bioactive compounds in natural treatments, with the objective of validating therapeutic candidates and ultimately, developing treatments for neurodegenerative ailments like amyotrophic lateral sclerosis, which is also known as Lou Gehrig’s Disease.

The enterprise’s product pipeline comprises of a gene therapy program termed ALPHA-0602 for the treatment of Lou Gehrig’s Disease, which delivers a neurotrophic protein known as granulin; and an acetylcholine esterase inhibitor dubbed ALPHA-1062, which has been developed to treat mild traumatic brain injuries and dementia of the Alzheimer’s type. ALPHA-1062 is currently in a pivotal relative bioavailability study. Thus far, the formulation has demonstrated improved tolerability and safety in human clinical trials.

The company plans to submit a New Drug Application for its ALPHA-1062 formulation which has shown promise in treating mild to moderate Alzheimer’s disease. The formulation’s success and approval will not only benefit patients suffering from this indication but also will bring in additional revenue and investments into the company, which will be good for its growth.

Alpha Cognition (ACOGF), closed Monday's trading session at $1.02, up 3.0303%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 1,000 and the stock's 52-week low/high is $0.6761/$1.80.

Shapeways Holdings (SHPW)

We reported earlier on Shapeways Holdings (SHPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shapeways Holdings Inc. (NYSE: SHPW) is a digital manufacturing company that is engaged in designing, manufacturing and selling 3D printed products.

The firm has its headquarters in Long Island City, New York and was incorporated in 2008. Prior to its name change, the firm was known as Galileo Acquisition Corp. It operates as part of the printing and related support activities industry. The firm has nine companies in its corporate family and serves consumers around the globe, with a focus on Europe and the United States.

The company operates under a single segment, which offers 3D printing services to consumers. It is focused on providing digital manufacturing software solutions that increase access to industrial-grade additive manufacturing through the digitization of the end-to-end manufacturing process.

The enterprise uses about 10 additive manufacturing technologies to produce parts in roughly 90 finishes and materials. It offers services to 3D designers through its website, allowing them to upload and print their models. It uses its digital manufacturing platform to transform these digital designs into physical products.The enterprise’s software also supports consumers through the design, production, manufacturing and delivery process. In addition to this, its website provides a marketplace that allows designers to sell and share their products, which includes a range of personalized custom-made items like art products and jewelry.

The company is focused on growing its proprietary software platform and accelerating its investments to drive new sales growth by scaling its business development capabilities and using new 3D manufacturing technologies which will all have a positive influence on its growth.

Shapeways Holdings (SHPW), closed Monday's trading session at $3.77, up 1.6173%, on 205,547 volume with 1,562 trades. The average volume for the last 3 months is 205,484 and the stock's 52-week low/high is $3.36/$12.81.

Civeo Corp. (CVEO)

Wall Street Resources, MarketBeat, INO.com Market Report, Marketbeat.com, MarketClub Analysis, StockMarketWatch, QualityStocks, StreetInsider, StreetAuthority Daily, StockOodles, The Street, Wall Street Mover, Barchart, BUYINS.NET, Dividend Opportunities, Energy and Capital, Wealthpire Inc., InvestorPlace, Money Morning, Wealth Daily, TopStockAnalysts, AllPennyStocks, Top Pros' Top Picks, Zacks and Jason Bond reported earlier on Civeo Corp. (CVEO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corporate Update

Civeo Corp. (NYSE: CVEO) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “Growing Cap-Ex Budgets From Oil Sands Producers Support Healthier Civeo Occupancy Levels In 2022; Note Civeo’s Improving Balance Sheet And Strong Cash Flow; Maintain $30 Price Target.”

Click here to access the full report.

About Civeo Corp.

Civeo is a leading provider of hospitality services with prominent market positions in the Canadian oil sands and the Australian natural resource regions. Civeo offers comprehensive solutions for lodging hundreds or thousands of workers with its long-term and temporary accommodations and provides food services, housekeeping, facility management, laundry, water and wastewater treatment, power generation, communications systems, security and logistics services. Civeo currently operates a total of 28 lodges and villages in Canada, Australia and the U.S., with an aggregate of approximately 30,000 rooms. Civeo is publicly traded under the symbol CVEO on the New York Stock Exchange. Please visit www.civeo.com.

Civeo Corp. (CVEO), closed Monday's trading session at $19.29, up 0.625978%, on 29,850 volume with 461 trades. The average volume for the last 3 months is 29,850 and the stock's 52-week low/high is $13.09/$25.28.

The QualityStocks Company Corner

Growth Capital Acquisition Corp. (NASDAQ: GCAC)

The QualityStocks Daily Newsletter would like to spotlight Growth Capital Acquisition Corp. (NASDAQ: GCAC).

Growth Capital (NASDAQ: GCAC), a publicly traded special purpose acquisition company listed on Feb. 2, 2021, recently announced its entry into a definitive business combination agreement with Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance Micro Motion Technology (“MMT”(R)) lidar solutions. “Upon closing of the transaction, the combined company will be renamed ‘Cepton Inc.’ and is expected to be listed on the Nasdaq stock exchange under new ticker symbol CPTN,” reads a recent article. “Cepton Technologies Inc. is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (‘ADAS/AV’), smart cities, smart spaces and smart industrial applications. General Motors (NYSE: GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented MMT lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.” To view the full article, visit https://ibn.fm/yZKrv

Growth Capital Acquisition Corp. (NASDAQ: GCAC), a publicly traded special purpose acquisition company listed on February 2, 2021, with $172.5 million in Trust, and Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance MMT® lidar solutions, on August 5, 2021, announced their entry into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed ‘Cepton Inc.’ and is expected to be listed on the Nasdaq stock exchange under new ticker symbol ‘CPTN’.

The proposed business combination, which has been unanimously approved by the boards of directors of Cepton and Growth Capital, is expected to be completed early in the first quarter of 2022, subject to, among other things, approval by Growth Capital’s stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions.

Cepton Technologies Inc. is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s proposed merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Growth Capital Acquisition Corp. (NASDAQ: GCAC), closed Monday's trading session at $9.94, up 0.100705%, on 11,592 volume with 36 trades. The average volume for the last 3 months is 11,589 and the stock's 52-week low/high is $9.55/$9.99.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

  • Flora Growth Corp. is a Canadian cannabis and wellness brand distributor operating from a cultivation base in central Colombia
  • The company’s focus on sustainability guides its efforts to market products that are beneficial to their local communities as well as the world at large
  • Market analysts predict 2022 will see the global CBD skin care market segment alone grow with a CAGR of 24.8 percent
  • The COVID-19 pandemic is continuing to drive expansion of online retail that affects the cosmetics sector as well as clothing, groceries and other avenues that may include the more-than-190 cannabis-derivative products produced by Flora Growth 

Plant-based wellness and lifestyle collective Flora Growth (NASDAQ: FLGC) is entering 2022 with momentum from the past year’s aggressive growth campaign for its global cannabis-derivative brand distribution of pharmaceuticals, cosmetics and nutraceuticals.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $1.95, up 9.5506%, on 1,006,911 volume with 3,537 trades. The average volume for the last 3 months is 1.007M and the stock's 52-week low/high is $1.68/$21.45.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Studying tumor growth and treatment is a crucial part of cancer research because it aids in the development of more effective treatments. Despite decades of research, however, drug identification for the treatment of brain cancer is still slow. This is mainly due to the lack of better models for research. This may soon change after Uppsala University researchers used artificial intelligence (“AI”) to develop a new technique to study brain cancer. The technique is based on the transplantation of tumor cells to zebrafish embryos, which are then observed using AI. This technique can partially replace the mouse models that are currently being used to study the growth of tumors and tumor treatments. The use of mouse models is often costly, time consuming and difficult. This is in addition to not allowing the observation of the growth of tumors in living tissue, which is why it’s crucial to find alternative methods. Other researchers involved in the study include Cecilia Krona, Katarzyna Koltowska, Neda Hekmati, Rebecka Stockgard, Marleen Gloger and Elin Almstedt. The study was published in the “Neuro-Oncology” scientific journal. It is beneficial that new approaches to conducting studies are coming up. Such novel techniques improve the odds that entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) will move faster and more affordably in their quest for better brain cancer treatments.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.772, up 9.9089%, on 247,359 volume with 731 trades. The average volume for the last 3 months is 247,255 and the stock's 52-week low/high is $0.6924/$4.46.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Monday's trading session at $0.165, up 1.8519%, on 16,338,771 volume with 1,544 trades. The average volume for the last 3 months is 16.339M and the stock's 52-week low/high is $0.0079/$0.659.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms
  • Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to improve access to health benefits and reframe the conversation on psychedelics.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.114, up 9.4102%, on 20,959 volume with 15 trades. The average volume for the last 3 months is 20,959 and the stock's 52-week low/high is $0.10/$1.038.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing technology space, today announced that its CEO Matthew Moore has been invited to present at the Emerging Growth Conference. Moore’s presentation is slated to begin at 3 p.m. ET on Wednesday, Jan. 5, 2022, where he will highlight InnerScope’s two recent direct-to-consumer hearing aid company acquisitions of iHear Medical Inc. and HearAssist II LLC. In addition, Moore will discuss InnerScope’s 2022 growth trajectory with these pivotal acquisitions and a key partnership with Atlazo Inc., a leader in intelligent semiconductor solutions, to develop new types of unprecedented artificial intelligence hearing products. Interested parties should visit https://ibn.fm/xiCFA to register for the event and receive any updates. An archived webcast will also be made available on EmergingGrowth.com for attendees unable to join the event live on the day of the conference. To view the full press release, visit https://ibn.fm/BiKo1

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Monday's trading session at $0.0113, up 13%, on 30,402,799 volume with 487 trades. The average volume for the last 3 months is 30.403M and the stock's 52-week low/high is $0.000155/$0.098.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • In an interview with Authority Magazine’s Charlie Katz, Rositano Jr. discussed the early years of the Fan Pass Live artist platform and how he and his brother (and business partner) found their niche with music and entertainment
  • The interview includes an in-depth look at Rositano Jr.’s approach and unique business model, as well as what his role as CEO of Friendable and Fan Pass implies
  • Rositano Jr. also offered valuable tips and advice for budding entrepreneurs, including the things he wished he knew before he ever became a founder

In a recent interview conducted by Charlie Katz for Authority Magazine, Robert A. Rositano Jr., co-founder, and CEO of mobile technology and marketing company Friendable (OTC: FDBL), added his story to the ongoing “5 Things I Wish Someone Told Me Before I Became A Founder” series (https://ibn.fm/86lxN). Authority Magazine offers in-depth interviews with those who hold “authority” in industries such as business, pop culture, wellness, tech, and more. Katz is the Executive Creative Director at Bitbean Software Development. Friendable’s (OTC: FDBL) CEO and Co-Founder Robert Rositano Jr. was recently featured on the Hellblazer Biz Podcast. Rositano joined Chris Gordon, the program’s host, to discuss ventures with his brother, Dean Rositano, where the two have worked together as business partners, for almost 30 years, sharing a passion for the music industry. “In the early 2000s, the brothers worked with a major industry name to produce a new venture/revenue stream for independent artists. Together with the help of Herbie Herbert and his partner Bill Graham and their recording studio, the brothers would record artists and invite friends, family and fans to go online and vote for their favorite groups, purchase merchandise and more. This venture was what brought about the birth of the Fan Pass Live artist platform,” reads a recent article. “Over the years, technological advancements have made the Rositano brothers’ idea from the early 2000s more conducive.” Rositano discussed such advancements that have driven industry progress, including Wi-Fi as a major contributor given that wireless connections allow continuous consumption of content, music in particular. “We were trying to elevate the careers of these indie artists by not only giving them exposure, but a way to earn, utilizing the internet,” Rositano said, underlying freedom and control as key advantages of the Fan Pass platform. “It’s really always been about entertainment, music, educating – whether it’s an artist or a fan – and trying to provide technology and services that allow them to do that and have freedom and control.” To view the full article, visit https://ibn.fm/HIajB

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday's trading session at $0.00295, up 0.854701%, on 2,689,633 volume with 34 trades. The average volume for the last 3 months is 2.251M and the stock's 52-week low/high is $0.0026/$0.0649.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

The opioid pandemic has wreaked havoc across America for decades, taking hundreds of thousands of lives from 1999 and leaving millions of Americans with substance use disorder. The prevalence of pharmaceutical drugs as well as the increased accessibility of illicit drugs such as heroin has made it nearly impossible to effectively end the opioid crisis. And since addiction and drug use tends to have extremely negative stereotypes, addicts tend to shy away from seeking treatment. For several lawmakers and drug reform groups, the first thing to do was reduce opioid deaths. From April 2020 to April 2021, America lost an estimated 100,000 people to opioid overdoses, significantly underscoring the need for immediate action. Ironically, one of the most controversial solutions to opioid deaths —safe-consumption sites — has proven to be quite effective at preventing individuals from succumbing to opioid overdoses. These sites are locations where people suffering from drug addiction can consumer illicit drugs under the supervision of trained medical professionals to prevent overdose deaths. There may be some benefit to determining how this harm-reduction effort can benefit from cutting-edge devices such as the smart inhalers and dose-measuring devices commercialized by companies such as RYAH Group Inc. (CSE: RYAH) since the technology has the capacity to regulate the dosage consumed.

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Monday's trading session at $0.045, even for the day, on 312,600 volume with 13 trades. The average volume for the last 3 months is 473,709 and the stock's 52-week low/high is $0.03/$0.20.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

  • Global supply chain disruptions are set to spread to the North American cannabis market
  • Supply shortages are already being felt in the manufacture of vaping devices and specialty packaging with rising concerns that these could extend to raw cannabis flower supply
  • American Cannabis Partners has distinguished itself through both a strict focus on a vertically integrated business model as well as through its adherence to unique Jamaican cultivation techniques
  • The company now has plans to expand operations to a third state in 2022 and a fourth state by 2024

A shortage of Nutella and new automobiles, higher gas prices, and delayed deliveries on Christmas presents can all be linked to ongoing and major disruptions in the global supply chain. However, and in a largely unforeseen twist, shortages have now extended to the North American cannabis market. Rolling power outages in China, incessant shipping disruptions and the upcoming Chinese Lunar New Year holiday are increasingly set to play havoc on the global cannabis supply chain. The shortages and resulting impact on cannabis supply has led to a greater premium being placed on vertically integrated producers, with American Cannabis Partners (“ACP”) — a multi-state 100% organic cannabis cultivation company headquartered within Northern California’s Emerald Triangle — a key proponent of the business model.

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News

chart

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR).

  • FingerMotion received approval for its application for NASDAQ up-listing, and commenced trading on Tuesday, December 28, 2021, under the company’s current trading symbol, “FNGR”
  • The approval marks a key milestone for the company as it plans to execute an ambitious growth strategy for the 2022 calendar year
  • It marks FingerMotion’s second successful up-listing application with the first one (for the OTCQB Venture Marketplace) having gone through back in February 2019

FingerMotion (NASDAQ: FNGR) just announced listing its shares of common stocks on The Nasdaq Stock Market LLC (“Nasdaq”). The approval, which came on December 27, 2021, has seen FingerMotion become the latest technology company listed on the Nasdaq Capital Market, a move that offers the company great exposure within the investment community (https://ibn.fm/J8qfA).

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Monday's trading session at $6.07, off by 14.6273%, on 45,662 volume with 425 trades. The average volume for the last 3 months is 45,332 and the stock's 52-week low/high is $3.22/$17.00.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • Eat Well Investment Group has appointed Marc Aneed, the current President and Director, as its new CEO
  • Mr. Aneed has over 20 years’ experience in the consumer-packaged goods (“CPG”) space, having worked on and launched multiple successful consumer products at The Quaker Oats Company and Glanbia PLC
  • Eat Well, a company that combines the best of agribusiness, food tech, and consumer goods, is building a platform that covers all the segments of the supply chain
  • The company expects to leverage the guidance from its management and advisory team to grow through acquisitions, the launch of new products, expanded contracts, and more

Fully-integrated seed-to-market company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) recently appointed the current President and Director, Marc Aneed, as its new Chief Executive Officer (“CEO”), taking over from David Doherty who has retired (https://ibn.fm/fXEuU).

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Monday's trading session at $0.4675, off by 1.0163%, on 11,630 volume with 9 trades. The average volume for the last 3 months is 11,630 and the stock's 52-week low/high is $0.1001/$1.00.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it has received fast track designation (“FTD”) from the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate: REQORSA(TM) Immunogene Therapy. The designation is for REQORSA in combination with Merck & Co’s Keytruda(R) in patients with histologically confirmed unresectable stage III or IV non-small cell lung cancer (“NSCLC”) whose disease progressed after treatment with Keytruda. According to the announcement, GNPX plans to start its Acclaim-2 clinical trial Q1 2022. The trial open-label, multicenter Phase 1/2 clinical trial is designed to evaluate REQORSA in combination with Keytruda for this patient population. This is the second FTD the company has received for REQORSA. “We are thrilled to receive a second fast track designation from the FDA for REQORSA in patients with late-stage NSCLC, this time in combination with the checkpoint inhibitor Keytruda,” said Genprex president and CEO Rodney Varner in the press release. “This Fast Track Designation is an important step in our efforts to accelerate clinical development of REQORSA and another validation of the potential of REQORSA to treat the unmet medical need of patients with late-stage NSCLC. With a strong balance sheet of $42 million in cash as of the end of the third quarter of 2021 and expert clinical trial management led by chief medical officer and industry veteran Mark Berger, MD, who joined Genprex in September 2021, we are well positioned to advance our Acclaim-1 and Acclaim-2 clinical trials in a meaningful way in 2022.” To view the full press release, visit https://ibn.fm/Uxz6k

Genprex Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Monday's trading session at $3.5, up 167.1756%, on 248,553,285 volume with 583,220 trades. The average volume for the last 3 months is 238.95M and the stock's 52-week low/high is $1.17/$7.72.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading